Patents by Inventor Michel Major

Michel Major has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fault-tolerant computer for reconfigurable hardware devices
    Patent number: 11966284
    Abstract: A fault-tolerant computer system includes a plurality of processors configured to simultaneously execute identical sets of processor-executable instructions, each of the plurality of processors containing a processor core including one or more registers and a local memory, an arbiter configured to read each of the registers of the plurality of processors, detect incorrect register values, and overwrite the registers containing the incorrect register values with corrected register values, and a memory scrubber configured to read each address of the local memories of the plurality of processors, detect incorrect memory values, and overwrite addresses containing the incorrect memory values with corrected memory values. In various embodiments, the computer system may be implemented using one or more field programmable gate arrays (FPGAs).
    Type: Grant
    Filed: October 10, 2023
    Date of Patent: April 23, 2024
    Assignees: MONTANA STATE UNIVERSITY, RESILIENT COMPUTING, LLC
    Inventors: Brock J. Lameres, Christopher Michel Major
  • Synthetic particulate vectors and preparation process
    Patent number: 6759060
    Abstract: A synthetic particulate vector comprising a non-liquid hydrophilic nucleus which does not have an external lipid layer grafted thereon. A method for preparing a particulate vector by encapsulating an ionizable active principle, vectors obtainable through said method, and pharmaceutical, cosmetological or food compositions containing such vectors are also disclosed.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: July 6, 2004
    Assignee: Biovector Therapeutics, S.A.
    Inventors: Daniel Samain, Igancio De Miguel, Frédérique N'guyen, Pascal Delrieu, Li Ding, Nadine Candelotto, Corinne Segreto, Didier Betbeder, Roger Kravtzoff, Michel Major
  • Use of particle vectors in immunomodulation
    Publication number: 20040081686
    Abstract: The invention pertains to use of a vector of the type comprising a nonliquid hydrophilic core for the preparation of a medication intended for the treatment of cancers and/or viral diseases, the vector being combined in the medication with at least one substance other than an antigen capable of modulating the immune response.
    Type: Application
    Filed: October 25, 2002
    Publication date: April 29, 2004
    Applicants: Biovector Therapeutics, Institut Gustave-Roussy
    Inventors: Roger Kravtzoff, Didier Betbeder, Michel Major, Olivier Balland, Samir El Mir, Frederic Triebel, Anne Casanova
  • SYNTHETIC PARTICULATE VECTORS AND PREPARATION PROCESS
    Publication number: 20020168408
    Abstract: A synthetic particulate vector comprising a non-liquid hydrophilic nucleus which does not have an external lipid layer grafted thereon. A method for preparing a particulate vector by encapsulating an ionizable active principle, vectors obtainable through said method, and pharmaceutical, cosmetological or food compositions containing such vectors are also disclosed.
    Type: Application
    Filed: July 9, 1998
    Publication date: November 14, 2002
    Inventors: DANIEL SAMAIN, IGANCIO DE MIGUEL, FREDERIQUE N'GUYEN, PASCAL DELRIEU, LI DING, NADINE CANDELOTTO, CORINNE SEGRETO, DIDIER BETBEDER, ROGER KRAVTZOFF, MICHEL MAJOR
  • Mucosal administration of substances to mammals
    Patent number: 6096291
    Abstract: A novel method for the mucosal administration of a substance to a mammal is provided. The method comprises contacting a mucosal surface of the mammal with the substance in combination with a Biovector. The Biovector has a core that comprises a natural polymer, or a derivative or a hydrolysate of a natural polymer, or a mixture thereof. A preferred natural polymer is a polysaccharide or an oligosaccharide. The core is optionally coated with an amphiphilic compound, such as a lipid.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: August 1, 2000
    Assignee: Biovector Therapeutics, S.A.
    Inventors: Didier Betbeder, Alain Etienne, Ignacio de Miguel, Roger Kravtzoff, Michel Major
  • Mucosal administration of substances to mammals
    Patent number: 6017513
    Abstract: A novel method for the mucosal administration of a substance to a mammal is provided. The method comprises contacting a mucosal surface of the mammal with the substance in combination with a Biovector. The Biovector has a core that comprises a natural polymer, or a derivative or a hydrolysate of a natural polymer, or a mixture thereof. A preferred natural polymer is a polysaccharide or an oligosaccharide. The core is optionally coated with an amphiphilic compound, such as a lipid.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: January 25, 2000
    Assignee: Biovector Therapeutics, S.A.
    Inventors: Didier Betbeder, Alain Etienne, Ignacio de Miguel, Roger Kravtzoff, Michel Major